Physician profile
Michael D Dupre
NPI 1104802495
$11,515.84
in general payments reported to CMS, 2019-2025
56 companies · $1,784 in 2025
The $1,784 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $1,376 · 2021: $888 · 2022: $2,165 · 2023: $2,367 · 2024: $1,948 · 2025: $1,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,079 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,078.70 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,783.09 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,590.19 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $1,039.59 | 2019-2025 | Otezla, Repatha, Otezla |
| Medtronic Minimed, INC. | $681.91 | 2019-2020 | |
| Pfizer INC. | $667.84 | 2019-2025 | |
| Lilly USA, LLC | $605.49 | 2019-2024 | Mounjaro, Emgality, Jardiance |
| Glaxosmithkline, LLC. | $591.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Neurocrine Biosciences, INC. | $382.26 | 2022-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $343.43 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $311.24 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $274.96 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $247.15 | 2019-2024 | Linzess |
| Sanofi-Aventis U.S. LLC | $224.76 | 2019-2022 | |
| Antares Pharma, INC. | $214.92 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Ardelyx, INC. | $214.54 | 2024-2025 | Ibsrela |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dupre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.